The mechanistic translation of nonclinical pharmacokinetic data to humans can make or break the success of your clinical plan.
Weight Loss Without Nausea: How QSP Modeling Can Optimize Obesity Treatments
Ozempic and Wegovy have been in the news for months as the first highly effective weight loss drugs on the market. However, a noted side effect—nausea—can make it difficult for patients to adhere to proper use.
Using QST Predictions to Optimize Your Drug, De-Risk Your Regulatory Submission, and Guide R&D
After investing years into developing and optimizing a new drug, it’s some of the worst news you can hear: your clinical trials are showing potential liver toxicity.
Mechanistic dissolution data modeling for PBBM introduction: The P-PSD approach
Collect input data for dissolution modeling and test multiple conditions
Ionization Prediction Summit Webinar Series: Session 4 Experimental Aspects of pKa Measurements
Multiprotic ionization is often poorly understood in the pharmaceutical industry.
Ionization Prediction Summit Webinar Series: Session 1 Fundamentals of Ionization
In the Ionization Prediction Summit webinar series, leading industry experts will explain ionization, how ionization modeling works, how ionization models are influenced by the large amounts of industrial data...
Capture and Use of Meaningful Data for Population PK/PD Analysis with Non-Linear Mixed Effects Modeling
Your model is only as good as your data!
From Target Identification to Novel Lead: How Multi-omics Analysis and AI-driven Drug Design Can Accelerate Early Drug Discovery
One of the key areas for optimization in the drug development process is the discovery stage. Traditional methods are time-consuming and often produce leads that ultimately fail.
Application of PBBM and virtual bioequivalence to support formulation development and define dissolution specification, two case studies
During this webinar, we will shed light on the key benefits and practical implications of utilizing in-silico modeling for formulation development, biopharmaceutical predictions, and bioequivalence studies.
QSP: The Best Kept Secret for Increasing the Technical Probability of Success in Clinical Trials & Enhancing Regulatory Submissions
Quantitative systems pharmacology (QSP) is no longer an “emerging field.”
Better Together: AI/ML, PBPK and QSP/QST Modeling in Drug Discovery & Development
Modeling and simulation offer useful predictions that can help guide your drug development program—but what if you could get even more out of the available technology?
In silico modeling as a support tool in the development of new products in the generic pharmaceutical industry: case studies of the application of DDDPlus™ and GastroPlus® software
During this webinar, we will shed light on the key benefits and practical implications of utilizing in silico modeling for formulation optimization, biopharmaceutical predictions, and bioequivalence studies
ADMET Predictor® 11 is Here: AI & ML for Drug Discovery and Development
Your competitors are using AI and machine learning for ADMET prediction—are you?
Using AI-driven Drug Design to Shorten Your Drug Development Process
In this webinar, Dr. Jeremy Jones, Principal Scientist, will discuss how artificial intelligence (AI) can be used in the drug discovery and development process to identify viable candidate molecules and shorten time to market.
Using GastroPlus®, PBBM and PKPD to Define Dissolution Safe Space in Support of Registration Specifications
If you’re curious how GastroPlus could be used to define dissolution safe space for your own projects, stream now.
PBPK Modeling for Identifying and Mitigating Absorption Risks in Early Drug Development
Physiologically based pharmacokinetic (PBPK) models represent animals and humans virtually as a collection of organs and tissues, each defined by a system of mathematical equations
What’s New in MonolixSuite 2023
Discover the new functionalities of MonolixSuite 2023 in this webinar!
NAFLDsym v2B Beta Release is Here: Insight into the Next Gen QSP Software Tool in Julia with Blazing Speed and Updated Interfacing
Join us in this webinar to learn about the technical advances made to the NAFLDsym platform in the latest release: version 2B Beta.
What’s New in GastroPlus® v9.8.3?
Learn about the new and improved functionality to drive advances to PBBM/PBPK applications from discovery through post-approval.
GastroPlus as an Educational Tool Teaching of Pharmacokinetics & Biopharmaceutics with PBPK Modeling
Students have an increased interest in learning physiologically based pharmacokinetic (PBPK) modeling, but this requires an in-depth understanding of biopharmaceutics and pharmacokinetics.